keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer neuropathy

keyword
https://www.readbyqxmd.com/read/28620884/kinetic-pharmacodynamic-model-of-chemotherapy-induced-peripheral-neuropathy-in-patients-with-metastatic-breast-cancer-treated-with-paclitaxel-nab-paclitaxel-or-ixabepilone-calgb-40502-alliance
#1
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, Kehua Wu, William T Barry, Clifford Hudis, Eric P Winer, Alan P Lyss, Deborah L Toppmeyer, Alvaro Moreno-Aspitia, Thomas E Lad, Mario Valasco, Beth Overmoyer, Hope Rugo, Mark J Ratain, Jogarao V Gobburu
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity caused by several chemotherapeutic agents. Currently, CIPN is managed by empirical dose modifications at the discretion of the treating physician. The goal of this research is to quantitate the dose-CIPN relationship to inform the optimal strategies for dose modification. Data were obtained from the Cancer and Leukemia Group B (CALGB) 40502 trial, a randomized phase III trial of paclitaxel vs. nab-paclitaxel vs. ixabepilone as first-line chemotherapy for locally recurrent or metastatic breast cancer...
June 15, 2017: AAPS Journal
https://www.readbyqxmd.com/read/28614979/docetaxel-induced-cardiac-respiratory-arrest-in-a-patient-with-chronic-atrial-fibrillation
#2
Mostaqul Huq, Tracie M Balvanz, Scott Mambourg
Docetaxel has been approved by the Food and Drug Administration for the treatment of many cancer types, including breast cancer, head and neck cancer, lung cancer, and prostate cancer. Many severe to life-threatening side effects (Grades 3-5) of docetaxel have been reported in clinical trials, case reports, and Food and Drug Administration Adverse Events Reporting System. These include anaphylactic reactions, febrile neutropenia, fluid retention, acute respiratory distress, pleural effusion, pneumonia, and peripheral neuropathy...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28577231/electronic-versus-paper-pencil-methods-for-assessing-chemotherapy-induced-peripheral-neuropathy
#3
Robert Knoerl, Evan Gray, Carrie Stricker, Sandra A Mitchell, Kelsey Kippe, Gloria Smith, William N Dudley, Ellen M Lavoie Smith
PURPOSE: The aim of this study is to examine and compare with the validated, paper/pencil European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20), the psychometric properties of three electronically administered patient reported outcome (PRO) measures of chemotherapy-induced peripheral neuropathy (CIPN): (1) the two neuropathy items from the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), (2) the QLQ-CIPN20, and (3) the 0-10 Neuropathy Screening Question (NSQ)...
June 2, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28572539/weekly-paclitaxel-and-cisplatin-as-neoadjuvant-chemotherapy-with-locally-advanced-breast-cancer-a-prospective-single-arm-phase-ii-study
#4
Liheng Zhou, Shuguang Xu, Wenjin Yin, Yanpin Lin, Yueyao Du, Yiwei Jiang, Yaohui Wang, Jie Zhang, Ziping Wu, Jinsong Lu
There was little evidence of weekly cisplatin regimen either for the locally advanced breast cancer or the metastatic setting. We aimed to evaluate that whether the combination of weekly paclitaxel and cisplatin could improve the efficacy of the neoadjuvant treatment for patients with locally advanced breast cancer. Patients with histologically confirmed large operable breast cancer received paclitaxel 80mg/m2 by weekly for 16 weeks and weekly cisplatin 25mg/m2 on day 1, 8 and 15, out of every 28 days for 4-week cycles...
May 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28551844/a-pilot-study-of-minocycline-for-the-prevention-of-paclitaxel-associated-neuropathy-accru-study-ru221408i
#5
Deirdre R Pachman, Travis Dockter, Patricia J Zekan, Briant Fruth, Kathryn J Ruddy, Lauren E Ta, Jacqueline M Lafky, Todor Dentchev, Nguyet Anh Le-Lindqwister, William M Sikov, Nathan Staff, Andreas S Beutler, Charles L Loprinzi
PURPOSE: Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Given that extensive animal data suggest that minocycline may prevent chemotherapy-induced neurotoxicity, the purpose of this pilot study was to investigate the efficacy of minocycline for the prevention of CIPN and the P-APS. METHODS: Patients with breast cancer were enrolled prior to initiating neoadjuvant or adjuvant weekly paclitaxel for 12 weeks and were randomized to receive minocycline 200 mg on day 1 followed by 100 mg twice daily or a matching placebo...
May 27, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28534351/the-short-term-safety-of-adjuvant-paclitaxel-plus-trastuzumab-a-single-centre-experience
#6
Ozturk Ates, Veli Sunar, Alma Aslan, Fatih Karatas, Suleyman Sahin, Kadri Altundag
PURPOSE: HER2-amplified breast cancer (BC) has a poor prognosis. The combination of trastuzumab with chemotherapy in the adjuvant setting decreases recurrence and improves overall survival in HER2-positive BC. However, the role of adjuvant treatment in patients with HER2-amplified small BC without lymph node involvement is still under debate. The purpose of this study was to investigate the safety of adjuvant paclitaxel and trastuzumab (APT) in this group of patients. METHODS: A total of 87 operated early BC patients without lymph node involvement (N0) were treated with APT for 12 weeks followed by trastuzumab alone for a total of 9 months...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28508185/titan-phase-iii-study-of-doxorubicin-cyclophosphamide-followed-by-ixabepilone-or-paclitaxel-in-early-stage-triple-negative-breast-cancer
#7
Denise A Yardley, Edward R Arrowsmith, Brooke R Daniel, Janice Eakle, Adam Brufsky, David R Drosick, Fred Kudrik, Linda D Bosserman, Mark R Keaton, Sharon A Goble, Jeffrey A Bubis, Victor M Priego, Kelly Pendergrass, Yvonne Manalo, Martin Bury, Donald S Gravenor, Gladys I Rodriguez, Roger C Inhorn, Robyn R Young, William N Harwin, Caryn Silver, John D Hainsworth, Howard A Burris
PURPOSE: Ixabepilone is a microtubule stabilizer with activity in taxane-refractory metastatic breast cancer and low susceptibility to taxane-resistance mechanisms including multidrug-resistant phenotypes and high β-III tubulin expression. Since these resistance mechanisms are common in triple-negative breast cancer (TNBC), ixabepilone may have particular advantages in this patient population. This study evaluated the substitution of ixabepilone for paclitaxel following doxorubicin/cyclophosphamide (AC) in the adjuvant treatment of early-stage TNBC...
May 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28494406/relative-dose-intensity-as-a-proxy-measure-of-quality-and-prognosis-in-adjuvant-chemotherapy-for-breast-cancer-in-daily-clinical-practice
#8
S J Schraa, K A Frerichs, M J Agterof, J C B Hunting, M Los, P C de Jong
AIM: Adjuvant chemotherapy treatment of women with breast cancer is frequently complicated by toxic side-effects, resulting in dose reduction and delay. In Dutch guidelines, a relative dose intensity (RDI) of at least 85% is recommended for optimal treatment. The aim was to investigate predictors of low RDI and its effect on prognosis. METHODS: All patients treated in the St. Antonius Hospital with adjuvant chemotherapy for breast cancer between 2008 and 2013 were included (N = 605)...
May 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28490901/breast-cancer-and-amyloid-bodies-is-there-a-role-for-amyloidosis-in-cancer-cell-dormancy
#9
Gerald J Mizejewski
Breast cancer and Alzheimer's disease (AD) are major causes of death in older women. Interestingly, breast cancer occurs less frequently in AD patients than in the general population. Amyloidosis, the aggregation of amyloid proteins to form amyloid bodies, plays a central role in the pathogenesis of AD and other human neuropathies by forming intracellular fibrillary proteins. Contrary to popular belief, amyloidosis is a common occurrence in mammalian cells, and has recently been reported to be a natural physiological process in response to environmental stress stimulations (such as pH and temperature extremes, hypoxia, and oxidative stress)...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28478849/differences-in-symptom-clusters-identified-using-symptom-occurrence-rates-versus-severity-ratings-in-patients-with-breast-cancer-undergoing-chemotherapy
#10
Carmen Ward Sullivan, Heather Leutwyler, Laura B Dunn, Bruce A Cooper, Steven M Paul, Yvette P Conley, Jon D Levine, Christine A Miaskowski
PURPOSE: One of the unanswered questions in symptom clusters research is whether the number and types of symptom clusters vary based on the dimension of the symptom experience used to create the clusters. Given that patients with breast cancer receiving chemotherapy (CTX), report between 10 and 32 concurrent symptoms and studies of symptom clusters in these patients are limited, the purpose of this study, in breast cancer patients undergoing CTX (n = 515), was to identify whether the number and types of symptom clusters differed based on whether symptom occurrence rates or symptom severity ratings were used to create the clusters...
June 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28469333/treatment-challenges-and-survival-analysis-of-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-in-real-world
#11
Praveen Adusumilli, Meher Lakshmi Konatam, Sadashivudu Gundeti, Stalin Bala, Lakshmi Srinivas Maddali
CONTEXT: Advent of trastuzumab has brought tremendous changes in the survival of human epidermal growth factor receptor 2 (Her2)-positive breast cancer patients. Despite the availability of the drug, it is still out of reach for many patients. There is very limited real world data regarding treatment challenges and survival analysis of these patients. AIMS AND OBJECTIVES: Primary objective is disease-free survival (DFS) and secondary objective is overall survival (OS) and toxicity profile...
January 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28447211/paclitaxel-induced-sensory-peripheral-neuropathy-is-associated-with-an-abcb1-single-nucleotide-polymorphism-and-older-age-in-japanese
#12
Yuko Tanabe, Chikako Shimizu, Akinobu Hamada, Kenji Hashimoto, Kazutaka Ikeda, Daisuke Nishizawa, Junko Hasegawa, Akihiko Shimomura, Yukinori Ozaki, Nobuko Tamura, Harukaze Yamamoto, Mayu Yunokawa, Kan Yonemori, Toshimi Takano, Hidetaka Kawabata, Kenji Tamura, Yasuhiro Fujiwara
PURPOSE: Whether age and inter-individual variability of pharmacogenetics are risk factors for paclitaxel-induced peripheral neuropathy (PIPN) is inconclusive. This study was conducted to evaluate the influence of previously investigated single nucleotide polymorphisms (SNPs) and age, using genotype data from a prospective study of paclitaxel-related toxicity in Japanese patients with breast cancer. METHODS: Peripheral blood mononuclear cells from 127 Japanese women with breast cancer who received weekly adjuvant paclitaxel were used to genotypes SLCO1B3 T334G (rs4149117), CYP2C8 A1196G (rs10509681), ABCB1 C1236T (rs1128503), ABCB1 G2677T/A (rs2032582), and ABCB1 C3435T (rs1045642)...
June 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28439763/a-phase-ii-multicenter-single-arm-study-of-tri-weekly-low-dose-nanoparticle-albumin-bound-paclitaxel-chemotherapy-for-patients-with-metastatic-or-recurrent-breast-cancer
#13
Shigeru Yamamoto, Noriko Maeda, Yukiko Nagashima, Hidefumi Kubo, Yoko Sato, Hiroto Matsui, Yuka Inoue, Yoshitaro Shindo, Shinsuke Kanekiyo, Kazuhiko Sakamoto, Nobuaki Suzuki, Shigeru Takeda, Tomio Ueno, Shigefumi Yoshino, Shoichi Hazama, Masaaki Oka, Hiroaki Nagano
BACKGROUND: Nanoparticle albumin-bound (nab)-paclitaxel is a solvent-free formulation of paclitaxel that is bound to albumin and has demonstrated improved progression free survival in previous studies of breast cancer. However, it is difficult to treat Japanese patients with metastatic or recurrent breast cancer with the recommended dose of 260 mg/m(2) of (nab)-paclitaxel for more than six cycles due to the occurrence of adverse events. To evaluate the treatment continuity and safety of low-dose nab-paclitaxel, we conducted a phase II study of nab-paclitaxel in patients with metastatic or recurrent breast cancer who had received up to one prior chemotherapy...
April 24, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28436999/clinical-practice-guidelines-on-the-evidence-based-use-of-integrative-therapies-during-and-after-breast-cancer-treatment
#14
REVIEW
Heather Greenlee, Melissa J DuPont-Reyes, Lynda G Balneaves, Linda E Carlson, Misha R Cohen, Gary Deng, Jillian A Johnson, Matthew Mumber, Dugald Seely, Suzanna M Zick, Lindsay M Boyce, Debu Tripathy
Answer questions and earn CME/CNE Patients with breast cancer commonly use complementary and integrative therapies as supportive care during cancer treatment and to manage treatment-related side effects. However, evidence supporting the use of such therapies in the oncology setting is limited. This report provides updated clinical practice guidelines from the Society for Integrative Oncology on the use of integrative therapies for specific clinical indications during and after breast cancer treatment, including anxiety/stress, depression/mood disorders, fatigue, quality of life/physical functioning, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep disturbance...
May 6, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28423524/critically-short-telomeres-and-toxicity-of-chemotherapy-in-early-breast-cancer
#15
Miguel Quintela-Fandino, Nora Soberon, Ana Lluch, Luis Manso, Isabel Calvo, Javier Cortes, Fernando Moreno-Antón, Miguel Gil-Gil, Noelia Martinez-Jánez, Antonio Gonzalez-Martin, Encarna Adrover, Raquel de Andres, Gemma Viñas, Antonio Llombart-Cussac, Emilio Alba, Silvana Mouron, Juan Guerra, Begoña Bermejo, Esther Zamora, Jose Angel García-Saenz, Sonia Pernas Simon, Eva Carrasco, María José Escudero, Ruth Campo, Ramón Colomer, Maria A Blasco
Cumulative toxicity from weekly paclitaxel (myalgia, peripheral neuropathy, fatigue) compromises long-term administration. Preclinical data suggest that the burden of critically short telomeres (< 3 kilobases, CSTs), but not average telomere length by itself, accounts for limited tissue renewal and turnover capacity. The impact of this parameter (which can be modified with different therapies) in chemotherapy-derived toxicity has not been studied.Blood from 115 treatment-naive patients from a clinical trial in early HER2-negative breast cancer that received weekly paclitaxel (80 mg/m2 for 12 weeks) either alone or in combination with nintedanib and from 85 healthy controls was prospectively obtained and individual CSTs and average telomere lenght were determined by HT Q-FISH (high-throughput quantitative FISH)...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28420987/curcumin-ameliorates-cisplatin-induced-nephrotoxicity-and-potentiates-its-anticancer-activity-in-sd-rats-potential-role-of-curcumin-in-breast-cancer-chemotherapy
#16
Parveen Kumar, Chandana C Barua, Kunjbihari Sulakhiya, Rajeev Kumar Sharma
Breast malignant neoplastic disease is one of the most complex diseases, as it is a multifactorial disease in which virtually all the targets are instantly or indirectly inter-reliant on each other. Cisplatin (CIS), an inorganic antineoplastic agent is widely utilized in the treatment of various solid tumors including breast cancer. Despite everything, its clinical use is limited, due to ototoxicity, peripheral neuropathy, and nephrotoxicity. The present work was directed to assess the combined result of curcumin (CUR) and CIS in 7, 12-dimethyl benz[a]anthracene (DMBA) induced breast cancer in rats and the prevention of nephrotoxicity induced by the latter...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28401365/discerning-the-clinical-relevance-of-biomarkers-in-early-stage-breast-cancer
#17
Tarah J Ballinger, Nawal Kassem, Fei Shen, Guanglong Jiang, Mary Lou Smith, Elda Railey, John Howell, Carol B White, Bryan P Schneider
PURPOSE: Prior data suggest that breast cancer patients accept significant toxicity for small benefit. It is unclear whether personalized estimations of risk or benefit likelihood that could be provided by biomarkers alter treatment decisions in the curative setting. METHODS: A choice-based conjoint (CBC) survey was conducted in 417 HER2-negative breast cancer patients who received chemotherapy in the curative setting. The survey presented pairs of treatment choices derived from common taxane- and anthracycline-based regimens, varying in degree of benefit by risk of recurrence and in toxicity profile, including peripheral neuropathy (PN) and congestive heart failure (CHF)...
April 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28376218/bmi-lifestyle-factors-and-taxane-induced-neuropathy-in-breast-cancer-patients-the-pathways-study
#18
Heather Greenlee, Dawn L Hershman, Zaixing Shi, Marilyn L Kwan, Isaac J Ergas, Janise M Roh, Lawrence H Kushi
Lifestyle factors may be associated with chemotherapy-induced peripheral neuropathy (CIPN). We examined associations between body mass index (BMI) and lifestyle factors with CIPN in the Pathways Study, a prospective cohort of women with invasive breast cancer. Methods: Analyses included 1237 women who received taxane treatment and provided data on neurotoxicity symptoms. Baseline interviews assessed BMI (normal: <25 kg/m 2 ; overweight: 25-29.9 kg/m 2 ; obese: ≥30 kg/m 2 ), moderate-to-vigorous physical activity (MVPA) (low: <2...
February 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28374323/gait-balance-and-patient-reported-outcomes-during-taxane-based-chemotherapy-in-early-stage-breast-cancer-patients
#19
Scott M Monfort, Xueliang Pan, Robyn Patrick, Bhuvaneswari Ramaswamy, Robert Wesolowski, Michelle J Naughton, Charles L Loprinzi, Ajit M W Chaudhari, Maryam B Lustberg
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of several commonly used chemotherapy drugs including taxanes, vinca alkaloids, and platinum compounds. Development of CIPN is highly variable, both in self-reported symptoms and functional consequences, and can be severe enough to alter dose intensity. PURPOSE: To describe the natural histories of both patient-reported symptoms of CIPN and functional impairments in breast cancer patients undergoing taxane-based chemotherapy...
April 3, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28366406/nab-paclitaxel-in-advanced-her2-negative-breast-cancer-patients-efficacy-and-safety-beyond-clinical-trials
#20
Antonio Bernardo, Raffaella Palumbo, Rebecca Pedersini, Elena Rota Caremoli, Anna Rita Gambaro, Antonella Ferzi, Francesca Riva, Donatella Grasso, Marco Danova, Emiliana Tarenzi, Valter Torri, Marina E Cazzaniga
BACKGROUND: Few data are available regarding efficacy and safety of nanoparticle albumin-bound (nab)-paclitaxel in advanced breast cancer patients outside a controlled trial, especially for the weekly schedule. PATIENTS AND METHODS: We prospectively collected data of advanced breast cancer patients who were candidates to be treated with weekly (125 mg/m(2) for 3 consecutive weeks followed by a 1-week rest) or every 3 weeks (260 mg/m(2)) schedules of nab-paclitaxel, according to physician's decision...
March 9, 2017: Clinical Breast Cancer
keyword
keyword
5718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"